quinazolines has been researched along with nintedanib in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amellal, N; Andre, T; Bouche, O; De Gramont, A; Ducreux, M; Lledo, G; Maindrault-Goebel, F; Merger, M; Stopfer, P | 1 |
| André, T; Battistella, A; Boudou, P; Cervera, P; Chibaudel, B; de Gramont, A; Dumont, S; El Ouadrani, K; Escargueil, AE; Fléjou, JF; Kamsu-Kom, N; Larsen, AK; Mégalophonos, VF; Ouaret, D; Petitprez, A; Poindessous, V; Tournigand, C | 1 |
| Döme, B; Török, S | 1 |
| Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S | 1 |
| Klempner, SJ; Mills, GB; Myers, AP; Westin, SN | 1 |
| Yaqub, F | 1 |
| Bloomfield, D; de Bono, JS; Fong, PC; Heath, C; Hickish, T; Jenkins, P; Jones, RJ; Karavasilis, V; Lumsden, G; Molife, LR; O'Sullivan, JM; Olmos, D; Omlin, A; Oommen, N; Pedley, I; Pelling, K; Temple, G; Thompson, E; Wheatley, D | 1 |
| Gordon, MS; LoRusso, PM; Ould-Kaci, M; Springett, GM; Su, YB; Wind, S; Zhao, Y | 1 |
| Amellal, N; Bahleda, R; Deutsch, E; Farace, F; Gazzah, A; Hollebecque, A; Marzin, K; Massard, C; Ould-Kaci, M; Roux, F; Soria, JC; Varga, A | 1 |
| Chiba, M; Gemma, A; Kubota, K; Matsumoto, M; Miyanaga, A; Nishijima, N; Noro, R; Seike, M; Soeno, C; Sugano, T | 1 |
| Diaz, J; Pandha, H; Sapunar, F; Sehgal, M; Takyar, S | 1 |
| Carillio, G; Costanzo, R; Daniele, G; Manzo, A; Montanino, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C | 1 |
| Alexandre, J; Allard, M; Arrondeau, J; Bellesoeur, A; Blanchet, B; Boudou-Rouquette, P; Chapron, J; Giraud, F; Goldwasser, F; Labat, L; Reis, R; Thomas-Schoemann, A; Vidal, M | 1 |
| Cai, J; Hilberg, F; Huang, Q; Liu, X; Mooers, BHM; Shen, T; Teng, P; Terzyan, SS; Wu, J; Zhou, M | 1 |
| Heymach, J; Nakano, T; Nowak, AK; Popat, S; Scagliotti, GV; Tsao, A | 1 |
6 review(s) available for quinazolines and nintedanib
| Article | Year |
|---|---|
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzenesulfonates; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib | 2012 |
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2012 |
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Topics: Antineoplastic Agents; Benzodioxoles; Carcinoma, Ovarian Epithelial; Erlotinib Hydrochloride; Female; Humans; Indazoles; Indoles; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides | 2013 |
First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Quality of Life; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2016 |
Angiogenesis Inhibitors in NSCLC.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyrroles; Quinazolines; Ramucirumab; Sorafenib; Sunitinib; Taxoids | 2017 |
Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
Topics: Asbestos; Bevacizumab; Carcinogenesis; Humans; Indoles; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Neovascularization, Pathologic; Pleural Neoplasms; Quinazolines | 2019 |
4 trial(s) available for quinazolines and nintedanib
| Article | Year |
|---|---|
Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Humans; Indoles; Male; Middle Aged; Quinazolines; Survival Rate | 2011 |
Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer.
Topics: Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Indoles; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prostatic Neoplasms, Castration-Resistant; Quinazolines; Treatment Outcome | 2014 |
A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors.
Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2015 |
Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours.
Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Quinazolines; Treatment Outcome | 2015 |
5 other study(ies) available for quinazolines and nintedanib
| Article | Year |
|---|---|
EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies.
Topics: Afatinib; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Proliferation; Cell Survival; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; HT29 Cells; Humans; Indoles; Mice; Mice, Nude; Protein-Tyrosine Kinases; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Xenograft Model Antitumor Assays | 2011 |
American Society of Clinical Oncology Annual Meeting 2013.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Medical Oncology; Multicenter Studies as Topic; Oximes; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Societies, Medical; Sulfones; Sunitinib; Taxoids; Treatment Outcome; Triazoles; United States | 2013 |
miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gefitinib; Gene Expression Profiling; Humans; Indoles; Inhibitory Concentration 50; Lung Neoplasms; MicroRNAs; Phenotype; Quinazolines; Receptor, Platelet-Derived Growth Factor beta; Receptors, Fibroblast Growth Factor; Receptors, Vascular Endothelial Growth Factor; Zinc Finger E-box-Binding Homeobox 1 | 2016 |
Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung canc
Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Crizotinib; Drug Monitoring; Drug Stability; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indoles; Limit of Detection; Lung Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2018 |
Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.
Topics: Animals; Binding Sites; Cell Line, Tumor; Crystallography, X-Ray; Drug Resistance, Neoplasm; Humans; Hydrophobic and Hydrophilic Interactions; Indoles; Mice; Molecular Dynamics Simulation; Mutagenesis, Site-Directed; Piperidines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-ret; Quinazolines; Recombinant Proteins | 2019 |